Coronavirus: Protein treatment trial 'a breakthrough'

Synairgen says preliminary results suggest its nebuliser treatment can lower the risk of disease.

The protein is inhaled directly into the lungs of patients with coronavirus, using a nebuliser, in the hope that it will stimulate an immune response.

The initial findings suggest the treatment cut the odds of a Covid-19 patient in hospital developing severe disease - such as requiring ventilation - by 79%.